(Q40933846)

English

Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies

scientific article published on August 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Epstein–Barr virus

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Riccardo Gavioli

9

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

author name string

Micheletti F

1

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Formentin A

3

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Canella A

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Marastoni M

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Bazzaro M

6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Tomatis R

7

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Traniello S

8

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

language of work or name

0 references

publication date

1 August 1999

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

European Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

2579-2589

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Expression of epstein-barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Effect of anchor residue modifications on the stability of HLA-A11/peptide complexes

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

The effect of anchor residue modifications on the stability of major histocompatibility complex class I-peptide interactions

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291521-4141%28199908%2929%3A08%3C2579%3A%3AAID-IMMU2579%3E3.0.CO%3B2-E

21 January 2018

Identifiers

10.1002/(SICI)1521-4141(199908)29:08<2579::AID-IMMU2579>3.0.CO;2-E

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40933846&oldid=1910877553"